. 2016 Mar 15;8(3):248–257. doi: 10.4251/wjgo.v8.i3.248

Table 4.

Ongoing neoadjuvant/borderline resectable trials

Trial	Registration No.	Treatment groups	Primary endpoint	Patients planned
NEONAX	NCT02047513	2 cycles Gem + nab-paclitaxel neoadjuvant	DFS	166
NEONAX	NCT02047513	4 cycles Gem + nab-paclitaxel adjuvant	DFS	166
		6 cycles Gem + nab-paclitaxel adjuvant
Perioperative mFOLFIRINOX	NCT02047474	3 cycles FOLFORINOX	DFS	46
Perioperative mFOLFIRINOX	NCT02047474	Neoadjuvant + adjuvant	DFS	46
NEOLAP	NCT02125136	2 cycles Gem + nab-paclitaxel	Conversion rate	168
		+ 2 × FOLFIRINOX		(including locally advanced PDAC)
		+ adjuvant 3 × Gem + nab-paclitaxel
		4 cycles Gem + nab-paclitaxel
		+ adjuvant 3 × Gem + nab-paclitaxel

DFS: Disease-free survival; PDAC: Pancreatic ductal adenocarcinomas.